<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPL) cause <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic disease</z:e> and recurrent pregnancy loss </plain></SENT>
<SENT sid="1" pm="."><plain>Despite their name it is now clear that the antigen for most <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> is the <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding protein beta(2) <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta(2)GPI) </plain></SENT>
<SENT sid="2" pm="."><plain>However, beta(2) <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I is only antigenic for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> when the protein is immobilised on a suitable surface such as <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> serine </plain></SENT>
<SENT sid="3" pm="."><plain>It has been suggested that <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> bind to beta(2) <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I on the surface of resting endothelial cells and this in turn leads to endothelial activation and the initiation of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>However, as <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> serine is absent from resting endothelial cell membranes, we questioned this hypothesis </plain></SENT>
<SENT sid="5" pm="."><plain>MATERIALS AND METHODS: The ability of human <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-containing sera and monoclonal <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> to interact with endothelial cells was examined using cell-based ELISAs employing human umbilical vein endothelial cells (HUVECs) as the antigen </plain></SENT>
<SENT sid="6" pm="."><plain>The expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules in response to treatment with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> was also measured by a cell-based ELISA </plain></SENT>
<SENT sid="7" pm="."><plain>Activation of NF kappa beta was examined using electrophoretic mobility shift assays (EMSAs) </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Neither monoclonal <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> nor human sera containing <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> bound to resting endothelial cells </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, one monoclonal <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> did bind to both activated and apoptotic endothelial cells </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> do not bind to resting endothelial cells nor do <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> activate resting endothelial cells </plain></SENT>
<SENT sid="11" pm="."><plain>Rather, an independent triggering event is required to activate endothelial cells and subsequently some <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> may then bind to the activated endothelial cells and initiate a thrombogenic process </plain></SENT>
</text></document>